Soin Therapeutics Completes Formulation Development for New Low-Dose Naltrexone Tablet to Treat Complex Regional Pain Syndrome
DAYTON, Ohio, Dec. 27 2021 / PRNewswire / – Soin Therapeutics, a biotechnology company based in Dayton, ohio, completed the formulation development work for their novel, Proprietary low dose naltrexone pill to treat complex regional pain syndrome (CRPS). CRPS is a debilitating orphan disease characterized by severe chronic pain, swelling, and hypersensitivity to touch, among other unwanted symptoms that typically affect the upper and / or lower extremities. The new proprietary formula developed by Soin Therapeutics has several unique characteristics, including how the drug will be released and absorbed into the body. The company hopes this will lead to significant improvement in symptoms in CRPS patients.
Soin Therapeutics Completes Formulation Development for New Low-Dose Naltrexone Tablet to Treat CRPS
Care Therapeutics recently received orphan drug status from the FDA for the use of low-dose naltrexone to treat CRPS. “The new formulation exhibits several beneficial features that are likely to be very useful in treating CRPS patients. As a practicing physician who treats these patients in my practice, I see the strong unmet need for a useful new treatment option to treat CRPS. CRPS, ânoted the pain. management specialist Dr. Amol Care, who is also the founder and CEO of Soin Therapeutics.
Dr. Amol Care “We plan to begin advanced-stage efficacy trials in 2022 in hopes of obtaining FDA approval once the trials are completed. Finally, help may be on the way for patients with CRPS. C is a debilitating disease, and we think we have something special with our new proprietary formulation that could have a huge impact. Care Therapeutics is looking forward to testing our solution in clinical sites across the world. United States soon.”
About Soin Therapeutics: Soin Therapeutics Inc (STI) is a biotechnology company based in Dayton, ohio and has developed several different drugs to treat several chronic diseases. Its flagship product, a proprietary new formulation of low-dose naltrexone, has received orphan drug status from the FDA to treat CRPS. STI plans to start a large, late-stage national efficacy trial in 2022 of its flagship product in CRPS patients. For more information contact Dr Amol Care at email@example.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/soin-therapeutics-completes-formulation-development-of-novel-low-dose-naltrexone-tablet-to-treat-complex-regional-pain-syndrome-301450834. html
SOURCE Treatment Therapeutics